Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.41 |
| ▸ | CXCR3 | P49682 | 8/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15347745 | 1.00 | DRD4 (0.42) | DRD4POLBHSD11B1CXCR3CHRM1 | |
| SCHEMBL30077139 | 0.92 | CXCR3 (0.51) | DRD4POLBHSD11B1CXCR3 | |
| SCHEMBL15347893 | 0.92 | CXCR3 (0.51) | DRD4POLBHSD11B1CXCR3 | |
| SCHEMBL30077029 | 0.91 | CXCR4 (0.46) | DRD4POLBHSD11B1CXCR4 | |
| SCHEMBL15347226 | 0.91 | CXCR4 (0.46) | DRD4POLBHSD11B1CXCR4 | |
| SCHEMBL30077152 | 0.90 | CXCR3 (0.47) | DRD4POLBHSD11B1CXCR3HRH3 | |
| SCHEMBL15347278 | 0.90 | CXCR3 (0.47) | DRD4POLBHSD11B1CXCR3HRH3 | |
| SCHEMBL15347512 | 0.90 | ACKR3 (0.42) | DRD4POLBHSD11B1CXCR3 | |
| SCHEMBL30077050 | 0.90 | ACKR3 (0.42) | DRD4POLBHSD11B1CXCR3 | |
| SCHEMBL15347471 | 0.89 | ACKR3 (0.41) | DRD4POLBHSD11B1CXCR3CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220348577-A1 | CXCR4 Receptor Antagonists | PROXIMAGEN LLC (US) | 2022-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220348577-A1 | CXCR4 Receptor Antagonists | CXCR4, CXCR1, CXCR2 | DRD4 1573/4885POLB 4392/4885HSD11B1 1779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.